title: Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer.
abstract: The cancer vaccine 105AD7 is an anti-idiotypic monoclonal antibody that mimics the tumour-associated antigen 791T/gp72 (CD55, Decay Accelerating Factor) on colorectal cancer cells. Phase I studies in patients with advanced disease confirmed that 105AD7 is non-toxic, and that T cell responses could be generated. A prospective, randomized, double-blind, placebo-controlled survival study in patients with advanced colorectal cancer was performed. 162 patients were enrolled between April 1994 and October 1996. Patients attended at trial entry, and at 6 and 12 weeks, where they received 105AD7 or placebo. Study groups were comparable in terms of patient demographics, and time from diagnosis of advanced colorectal cancer (277.1 v 278.6 days). Baseline disease was similar, with 50% of patients having malignancy in at least 2 anatomic sites. Compliance with treatment was poor, with only 50% of patients receiving 3 planned vaccinations. Median survival from randomization date was 124 and 184 days in 105AD7 and placebo arms respectively (P = 0.38), and 456 and 486 days from the date of diagnosis of advanced disease (P = 0.82). 105AD7 vaccination does not prolong survival in patients with advanced colorectal cancer. The reasons for lack of efficacy are unclear, but may reflect the high tumour burden in the patient population, and poor compliance with immunization. Further vaccine studies should concentrate on patients with minimal residual disease.
authors.affiliation: Division of Gastrointestinal Surgery, University Hospital, Queens Medical Centre, Nottingham, NG7 2UH, UK.
authors.forename: C A
authors.initials: CA
authors.lastname: Maxwell-Armstrong
authors.forename: L G
authors.initials: LG
authors.lastname: Durrant
authors.forename: T J
authors.initials: TJ
authors.lastname: Buckley
authors.forename: J H
authors.initials: JH
authors.lastname: Scholefield
authors.forename: R A
authors.initials: RA
authors.lastname: Robins
authors.forename: K
authors.initials: K
authors.lastname: Fielding
authors.forename: J R
authors.initials: JR
authors.lastname: Monson
authors.forename: P
authors.initials: P
authors.lastname: Guillou
authors.forename: H
authors.initials: H
authors.lastname: Calvert
authors.forename: J
authors.initials: J
authors.lastname: Carmichael
authors.forename: J D
authors.initials: JD
authors.lastname: Hardcastle
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology / Q000494:pharmacology*; D019496:Cancer Vaccines / Q000276:immunology / Q000494:pharmacology*; D002277:Carcinoma / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D015179:Colorectal Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D010919:Placebos; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: C405618:105AD7 antibody; D000888:Antibodies, Anti-Idiotypic; D019496:Cancer Vaccines; D010919:Placebos